Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales (Q38133728)

29 August 2017

title

Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales (English)

1 reference

29 August 2017

1

John P A Ioannidis

1 reference

29 August 2017

4

Kristian Thorlund

1 reference

29 August 2017

5

Edward J Mills

1 reference

29 August 2017

Fotini B Karassa

2

1 reference

29 August 2017

Eric Druyts

series ordinal

3

1 reference

29 August 2017

language of work or name

English

0 references

publication date

3 September 2013

1 reference

Nature Reviews Rheumatology

29 August 2017

published in

1 reference

29 August 2017

volume

9

1 reference

29 August 2017

issue

11

1 reference

29 August 2017

page(s)

665-673

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2013.134

29 August 2017

exact match

0 references

cites work

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Systematic review of the empirical evidence of study publication bias and outcome reporting bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Reference bias in reports of drug trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Multiple publication of reports of drug trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Reporting of outcomes in arthritis trials measured on ordinal and interval scales is inadequate in relation to meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Incomplete reporting of recruitment information in clinical trials of biologic agents for the treatment of rheumatoid arthritis: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Comparative effect sizes in randomised trials from less developed and more developed countries: meta-epidemiological assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Industry sponsorship and selection of comparators in randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Clinical trials in rheumatoid arthritis: a status report from the ClinicalTrials.gov website.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

What outcomes from pharmacologic treatments are important to people with rheumatoid arthritis? Creating the basis of a patient core set

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Poor reporting of search strategy and conflict of interest in over 250 narrative and systematic reviews of two biologic agents in arthritis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Methodological Report Phase I

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor alpha inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Mega-trials for blockbusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Therapies for active rheumatoid arthritis after methotrexate failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Lack of Head-to-head Trials and Fair Control Arms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Why the findings of published multiple treatment comparison meta-analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Inequities in access to biologic and synthetic DMARDs across 46 European countries

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

The first 2 years of the European Medicines Agency's policy on access to documents: secret no longer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.134

Sensitivity of effect variables in rheumatoid arthritis: a meta-analysis of 130 placebo controlled NSAID trials

31 March 2020

1 reference

12 December 2020

Adverse effects of biologics: a network meta-analysis and Cochrane overview

1 reference

12 December 2020

Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis

1 reference

12 December 2020

Beware of registries for their biases

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2013.134

1 reference

Dimensions Publication ID

29 August 2017

1019380329

0 references

1 reference